Full Press Release Details
Appoints Oliver Spandow to its Board of Directors
Executive Adds Significant Operational and M&A Expertise
ORANGE, NJ, August 13, 2018 - Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells
high performance liquid purification ultrafilters announced today the appointment of Oliver Spandow to its Board of Directors.
Spandow is currently the CFO, Executive Vice President and a member of the board of directors of IDOC, LLC, an optometry-based
consulting and member service organization. Prior to IDOC, Mr. Spandow spent 15 years with Johnson and Johnson (J&J), including
roles as the General Manager of the JNJ Vision Care business in the United Kingdom and Ireland, Vice President of Strategic Accounts
and Business Insights at Vistakon (J&J) USA, and Vice President, Finance and CFO of Vistakon (J&J) USA. While at JNJ,
in addition to general finance, sales and marketing roles, he was involved with multiple acquisitions, divestment, and licensing
deals. Prior to J&J, Mr. Spandow was a Management Consultant with Price Waterhouse. Mr. Spandow holds a B.S. in Finance from
the University of Connecticut and an MBA from the Fuqua School of Business, Duke University.
are very excited to have Oliver join our Board," said Daron Evans, CEO of Nephros. "Oliver's experience with
transactions and organization scale-up in the medical device space provides Nephros with a valuable resource as we continue to
focus on expansion."
Nephros team has done a great job over the last few years building a self-sustaining, growing business," said Mr. Spandow.
"I am excited to join the company's board at this time of rapid growth. I look forward to working closely with the
management team to help Nephros achieve its full growth potential in its core infection control and dialysis water businesses,
as well as participating in the evaluation of potential strategic steps to broaden its market segments and product portfolio."
is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as
a hemodiafiltration system for the treatment of patients with End Stage Renal Disease through its Specialty Renal Products, Inc.
subsidiary. Nephros filters or ultrafilters are used primarily in medical applications in various settings. These ultrafilters
are used by dialysis centers for assisting in the added removal of biological contaminants from the water and bicarbonate concentrate
supplied to hemodialysis machines and the patients. Additionally, Nephros ultrafilters are used in hospitals and medical clinics
for added protection in retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water. These ultrafilters
provide barriers that assist in improving infection control with showers, sinks, and ice machines.
more information about Nephros, please visit its website at www.nephros.com.
release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements
regarding the potential strategic steps, the anticipated benefits from Mr. Spandow's appointment to the Board of Directors
and other statements that are not historical facts, including statements which may be accompanied by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties
are detailed in Nephros's reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on
Form 10-K for the year ended December 31, 2017. Nephrosdoes not undertake any responsibility to update the forward-looking statements
Astor, Chief Financial Officer